Ubiquitination can influence the efficacy of cancer therapies. For instance, resistance to chemotherapeutic agents and targeted therapies can be mediated by changes in ubiquitination patterns. Inhibitors targeting specific components of the UPS, such as proteasome inhibitors, have been developed to counteract these resistance mechanisms. Bortezomib, a proteasome inhibitor, has shown success in treating multiple myeloma by disrupting protein homeostasis in cancer cells.
